Location:Home > Project Description > TX803

Our lead asset TX803 is a first-in-class small molecule therapeutics, with the potential to treat colorectal and other type of solid tumors.  TX803 is a non-kinase molecule that inhibits the PI3K/AKT pathway by targeting the truncated retiniod X receptor alfa (tRXRa) protein.  

tRXRa is found to be an oncoprotein through activation of PI3K and prevalent in tumor biopsy samples from colorectal and gastric cancer patients.

By targeting tRXRa, TX803 offers an alternative mechanism to inhibit PI3K/AKT pathway and potentially provides a better safety profile than direct PI3K inhibitors.

TX803 is active in several colon and breast cancer cell lines that carries the KRAS mutation, as well as in animal models.  Furthermore, TX803 induces apoptosis of these cancer cells in a synergistic manner with MEK inhibitors and the tumor inhibition effect was profoundly enhanced by dual pathway inhibition in animal studies.

Tarrex has licensed the worldwide rights to TX803 and its analogs from the Sanford-Burnham Medical Research Institute and is developing it as anon-cytotoxic, targeted cancer therapeutics.  Preclinical studies have demonstrated TX803 is orally active and well-tolerated in animals.  Tarrex has filed an IND with the US FDA and waiting to be cleared to start phase I clinical trials in the US.